CSPC’s bispecific fusion protein drug JMT-106 gains US IND clearance for GPC3-positive solid tumors
Jan. 16, 2024
CSPC Pharmaceutical Group Ltd. has announced FDA approval of an IND application for JMT-106, a bispecific fusion protein drug, for glypican-3 (GPC3)-positive solid tumors.